Tumor Associated Macrophage in Advanced Non-small Cell Lung Cancer

Tumor-Associated Macrophages Correlate With Response and Outcomes in Advanced Non-Small Cell Lung Cancer After First Line Treatment.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01551251

Enrollment

107

Registered

2012-03-12

Start date

2006-01-31

Completion date

2010-12-31

Last updated

2015-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Nonsmall Cell Lung Cancer

Brief summary

The purpose of this study is to investigate the effects of tumor associated macrophage (TAM) in advanced non-small cell lung cancer (NSCLC) patients on the treatment response and outcome of these subjects. Pathologic specimens from tissue bank will be stained by immunostaining methods with CD68 antibody. The clinical treatment response and outcomes will be analyzed between high or low TAM.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* advanced NSCLC, * more than 20 years old, * measurable tumor, * response and outcome recorded after the first line treatment.

Exclusion criteria

* Early stage NSCLC, * less than 20 years, * pregnancy, * unmeasurable NSCLC.

Design outcomes

Primary

Measure	Time frame	Description
Response to treatment of advanced NSCLC with high or low TAM.	2-3 months	All patients with advanced non-small cell lung cancer (NSCLC) who had been treated were included. The decision of advanced NSCLC treatment was a consensus by the patient and clinician, and approved by team conference (including the oncologists, pulmonologists, pathologists, radiologists, surgeons, radiation oncologists, and nuclear medicine specialists). The tumor response was evaluated using computerized tomography according to the Response Evaluation Criteria in Solid Tumors (RECIST). The treatment response of advanced between high and low TAM patients were compared.

Secondary

Measure	Time frame	Description
Outcomes of advanced NSCLC with high and low TAM.	12-24 months	The outcomes of advanced NSCLC with high and low TAM will be compared. The outcomes include overall survival (OS) and progression-free survival (PFS). Survival curves were estimated by the Kaplan-Meier method while the log-rank test was used to compare the patient survival times per groups.

Countries

Taiwan

Outcome results